Investigational treatment shows promise for aggressive multiple myeloma

Results suggest bispecific antibody combination could improve outcomes

A new investigational treatment has shown strong and lasting responses in multiple myeloma patients with extramedullary disease (EMD), a particularly aggressive and difficult-to-treat form of the cancer.

Results from the phase 2 RedirecTT-1 study indicate a 78.9 percent overall response rate (ORR) with the combination of TALVEY (talquetamab) and TECVAYLI (teclistamab). These dual bispecific antibodies target both GPRC5D and BCMA, potentially improving response rates in heavily pretreated patients.

EMD occurs when myeloma cells form tumours outside the bones, often leading to poorer outcomes and limited treatment options. On average, patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM) and EMD have an ORR below 40 percent and median progression-free survival of less than six months.

Yael Cohen, head of the myeloma unit at Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, said: “The investigational combination of talquetamab and teclistamab has demonstrated deep, durable responses in patients with relapsed or refractory multiple myeloma, and now shows great promise in those with extramedullary myeloma, where standard therapies often fall short.”

The study enrolled 90 patients, with 84.4 percent being triple-class refractory. Among responders, 66.2 percent remained in response at the data cutoff, with a median follow-up of 13.4 months.

The combination therapy also showed a consistent safety profile, with low discontinuation rates due to adverse events. Patients had the option to switch to monthly dosing, which may improve tolerability.

The findings were presented at the 2025 European Hematology Association Congress. Researchers hope the results will lead to new treatment options for patients facing aggressive forms of multiple myeloma.